Because each of the major studies for SGLT2is, GLP1-RAs, and nsMRAs added these newer therapies to participants on the maximum label or tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), it is suggested that cardiorenal protective therapy begin with either an ACEi or an ARB, titrated to either the label maximum or the maximum tolerated dose (see Table 1 for list of currently approved ACEi and ARB in Canada and the maximally recommended dosing)
The data revealed a significant increase in GLP-1 levels, peaking at 30 min postinjection and subsequently decreasing over time
We critically evaluate the emerging evidence demonstrating that MSC Exos are enriched with anti-ferroptotic miRNAs, antioxidant enzymes, and iron homeostasis regulators, which can mitigate cellular ferroptosis
GLP-1 receptor agonists are linked to enhancements in kidney function
Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter
The Bottom Line Perimenopause and menopause weight gain stem from hormonal changes that can make traditional weight loss approaches feel like an uphill battle
